Loading
A phase 2 trial of HER2 PET in Breast cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging is a phase 2 interventional study registered as NCT07527806 by Peking University Cancer Hospital & Institute, with 156 participants planned, started 2026-05-01 and due to reach its primary completion in 2029-05-01. Interventions recorded: Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Docetaxel or Nab-paclitaxel, carboplatin, CDK4/6 inhibitor, Aromatase Inhibitor (AI), ADC. Conditions recorded: Breast Cancer.
Linked to the technology HER2 PET because the registry's title names it ("her2 pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2 PET, Breast cancer (all types) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Carboplatin, Breast cancer (all types) and the tag pipeline.
Shares Pertuzumab, Trastuzumab and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Pertuzumab, Trastuzumab and the tag pipeline.
Shares Pertuzumab, Trastuzumab and the tag pipeline.
Shares Pertuzumab, Trastuzumab and the tag pipeline.
Shares HER2 PET and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/